Conference Coverage
Conference Coverage
NAFLD patients with diabetes have higher fibrosis progression rate
Patients with type 2 diabetes had about a 2-year faster progression to fibrosis.
Conference Coverage
Dietary supplements hyped as LDL cholesterol lowering are a bust: SPORT
The list of supplements without effects on LDL in the placebo-controlled trial include commercial preparations of fish oil, cinnamon, garlic,...
Conference Coverage
Resmetirom reduces liver, CV risk factors in NASH with cirrhosis
“I do think it could be one of the drugs that really improves outcomes for patients with NASH.”
Conference Coverage
New trial suggests CV benefit with EPA: RESPECT-EPA
The open-label trial could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose...
Conference Coverage
Chinese herbal medicine may offer benefits in STEMI: CTS-AMI
Treatment with tongxinluo was tied to better outcomes out to 1 year, but observers say further data are needed to see how it may fit into STEMI...
Conference Coverage
Noninvasive tests may provide prognostic value in NAFLD
Fibrosis biomarkers were significantly predictive of event-free survival probability.
Conference Coverage
Precision CAD testing shows 70% cut in composite risk at 1 year
A streamlined protocol for evaluating suspected stable chest pain substantially improved outcomes at 1 year in the PRECISE trial.
Conference Coverage
Avoid routine early ECMO in severe cardiogenic shock: ECMO-CS
Early ECMO in this setting is increasingly common, but it didn’t seem to improve outcomes in the trial, compared with a more conservative approach...
Conference Coverage
ISCHEMIA-EXTEND: Conservative stable CAD management holds up
The ISCHEMIA trial results showed equipoise between conservative and invasive management of stable CAD. Extended follow-up strengthened the...
Conference Coverage
Study sheds new light on RAS inhibitors’ role for advanced CKD
“The results of this trial will inform future clinical practice worldwide and guideline recommendations.”
Conference Coverage
Moving the needle: SGLT2 inhibitor role for isolated kidney disease
When the EMPA-Kidney study began – before results from DAPA-CKD were known – “we never imagined such a large effect” on important endpoints in...